Tempus AI, Inc. TEM

The sharpest sourced fact on Tempus AI, Inc. today is the split between scale and loss. In its SEC EDGAR 10-Q for the period ended 31 March 2026, the company reported Revenue from Contract with Customer, Excluding Assessed Tax of $348.1M, while Net Income (Loss) Attributable to Parent was $-125.9M and Operating Income (Loss) was $-84.7M. This is not a quiet filing. It shows a business with real commercial volume and a cost base still pressing hard against it.

The supplied product rail makes the company more concrete than the ticker. The 10-Q says Tempus recognised revenue for clinical orders of $239.3M for the three months ended 31 March 2026, compared with $181.5M for the three months ended 31 March 2025. It also recognised Diagnostics revenue for direct bill orders of $21.8M, compared with $12.3M, and revenue from Insights products of $71.3M, compared with $49.5M. That tells the reader what the business is actually selling through this evidence pack: clinical orders, Diagnostics direct bill orders and Insights products, not just the broad promise implied by a company name with AI in it.

The balance sheet and cash-flow facts are just as important. The latest available SEC EDGAR financials supplied here show Assets of $2.14B, Liabilities of $1.72B, Stockholders' Equity Attributable to Parent of $416.4M and Cash and Cash Equivalents, at Carrying Value of $521.2M for the 10-Q period ending 31 March 2026. Net Cash Provided by (Used in) Operating Activities was $-73.3M, Payments to Acquire Property, Plant, and Equipment were $8.2M, Research and Development Expense was $48.2M, Inventory, Net was $51.8M, Increase (Decrease) in Inventories was $332,000, Earnings Per Share, Diluted was $-0.71, and Weighted Average Number of Shares Outstanding, Diluted was 178,964.

The source route is a filing route, not a chart route. The evidence names SEC EDGAR, the SEC filing index, the SEC submissions JSON, the SEC companyfacts JSON, a 10-Q dated 5 May 2026, an 8-K dated 13 May 2026, several Form 4 filings and a Form 144. It does not supply a TradingView route, a chart level, candle pattern, support area or valuation multiple, so those are not part of this file. The market mechanism visible here is the public-company mechanism: operating figures, cash use, convertible debt disclosure and insider filing activity.

The named development after the 10-Q is the 13 May 2026 SEC EDGAR 8-K. That filing includes a press release entitled “Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes,” dated 8 May 2026, and states that if the company redeems less than all outstanding Notes, at least $75.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption after the relevant notice. The evidence does not provide coupon economics, conversion terms, proceeds use beyond the supplied excerpts, or later balance-sheet impact.

The more recent public filing activity is concentrated in insider and sale-plan style filing trail: SEC EDGAR lists Form 4 filings dated 26 May 2026, 29 May 2026 and 3 June 2026, plus a Form 144 dated 27 May 2026. The supplied rail does not parse the transaction amounts or holder identities from those forms, so the proper claim is limited: the filings exist, they are current public developments, and they add governance and supply context without proving a trading signal on their own.